Newsletter
| Promoter: | Penny Stock Money Train | Paying Party: | Creme Dellatex |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| XYTS | $20000 | UNKNOWN |
| Max Profit: 85.71 % | Gain at close: 42.86 % | |
| *We think that this promoter is a part of a group of promoters. | ||
Good evening, Traders,
World-Wide Partnership Announced!
XYTS announced several days ago its partnership with DOVE Clinics!
Like XYTS, DOVE has been working in several areas of Integrated Advanced Medical Procedures along with Conventional Medicine.
XYTS has moved quickly to position itself to start treating patients in the United States with other geographic areas to be announced.
This is XYTS’s first step in its business model to announce multiple locations globally for the XYTS technology to be performed.
The partnership could allow for a significant increase in revenues for XYTS because European Patients interested in XYTS can now be immediately treated in the UK rather than XYTS losing patients that cannot travel to the States.
This positions XYTS strongly to continue its expansion processes throughout various worldwide geographic regions in order to control a larger portion of the immense market value of over forty seven billion.
-------------------------XYTS is on the Verge of Entering the Commercial Phase in the U.S.
Moreover, the results of one set of testing showed were so positive that 92% displayed the following impressive results:
- No evidence of cancer (38%)
- Symptoms of caner were gone (23%)
- Cancer relief was much improved (31%)
XYTS Has Multiple Applications Which Could Catapult Revenues
XyChloro Photodynamic Therapy – which XYTS utilizes - competes directly with chemotherapy and radiation therapy which only works on certain cancers and for a limited number of treatments…
…whereas XYTS could treat virtually ALL cancers.
But there’s even more to this story.
The Companies breakthrough cancer fighting technology also treats.
- Herpes
- AIDs
- Barrett's esophagus
- Gynecological
- Condyloma Acuminata
- Psoriasis
- Macular Degeneration
To read and see actual photos that show the success in treating these additional diseases, please visit the Company website: http://www.xytos.com
--------------------------------------
XYTS Positioned to Tap into Over Forty Billion Dollar Market
Now, XYTOS, Inc. could tap into the forty seven billion dollar cancer segment, one of the largest and fastest growing markets within the bio-technology industry.
Just look at some of the facts and figures...
- For the first time, cancer has surpassed heart disease as the top killer of Americans under 85.
- In 2002, 476,009 Americans under 85 died of cancer compared with 450,637 who died of heart disease.
- At over forty seven billion dollars, cancer is one of the largest, fastest growing markets in the pharmaceutical industry.
------------------------------------------
XYTS Cancer Treatment Has MAJOR Advantages over Chemotherapy There is a lot of media talk about "finding the cure for cancer". A cure implies certainty that the cancer has been removed and will not come back. There is no such certainty with any therapy. So, the best that therapies could achieve is to remove all evidence of cancer. However, unlike XYTS’s technology, conventional cancer therapies have limited repeatability. And both surgery and chemotherapy cannot be repeated indefinitely. However, with XYTS Cancer Treatment there is no limit on the number of times the experiment can be repeated... partly because it is non-toxic! XyChloro Photodynamic Therapy (XPDT) dramatically improves this situation. XYTS doctors administer an advanced Light Treatment, which creates singlet oxygen. It is this oxidant (singlet oxygen) that kills cancer cells (resulting in apoptosis). And, XYTS could achieve significant results with patients with later stage cancer